LL-37

People run it for stubborn infections — the chronic, biofilm-protected kind that antibiotics struggle with (Lyme and gut dysbiosis come up constantly) — and secondarily for wound healing and general immune modulation. The pitch is a broad-spectrum, your-own-biology antimicrobial that also calms inflammation and nudges tissue repair. Worth stating plainly up front: the way people run it — injected, for systemic infection — has essentially no efficacy trials behind it. The science is enormous but almost entirely lab-dish and animal.

It’s genuinely one of your own molecules — cleaved from the hCAP-18 protein stored in neutrophils and made in skin, gut, and airway lining as a first-line defense. That’s the appeal: not a foreign drug but an endogenous one you’re topping up. It’s also more than an antibiotic — the same peptide recruits immune cells, neutralizes bacterial endotoxin (LPS), and pushes wound closure, which is why it gets framed as a multitool. But the honest flip side is the headline: the same peptide is implicated in driving rosacea, psoriasis, and lupus. When LL-37 binds your own DNA or RNA it can flip from defender to alarm signal and feed autoimmune inflammation. “More is better” is exactly the wrong instinct here.

Two jobs in one molecule. As an antimicrobial it’s cationic and amphipathic — its positive charge is drawn to the negatively charged membranes of bacteria, where it inserts and forms pores or otherwise destabilizes the membrane until the cell ruptures, an action that also degrades biofilms. As an immune modulator it’s pleiotropic: it binds and neutralizes LPS (the endotoxin that triggers septic inflammation), chemoattracts neutrophils and monocytes, and promotes angiogenesis and re-epithelialization in wounds. The dangerous edge is the same chemistry — LL-37 complexes with self-DNA/RNA and ferries it into plasmacytoid dendritic cells, triggering interferon and the autoimmune cascade seen in psoriasis and lupus. Defender and instigator are the same mechanism pointed two ways.

Injection-site irritation and a histamine-type flush or itch are the most-mentioned acute effects — LL-37 is a known mast-cell activator, so that reaction is mechanistic, not incidental. The deeper concern isn’t an acute side effect at all: it’s that LL-37 is causally tied to inflammatory skin disease and systemic autoimmunity (rosacea, psoriasis, lupus) through the self-nucleic-acid pathway, so anyone with a personal or family history of autoimmune or inflammatory skin conditions has a real reason to avoid it. As with everything in this space the market is unregulated — a misfolded or impure peptide is both useless and a wildcard — so insist on a certificate of analysis. The plain truth: injected use is experimental, the safety record people are leaning on is short topical trials, not systemic dosing.

No established stack. It’s run as a targeted anti-infective in a defined block rather than layered into daily protocols, and pairing an autoimmune-implicated peptide with other immune-active compounds is the kind of thing the community has no data to support. People addressing gut or chronic infections tend to treat it as a standalone tool and stop when the course is done.